Compass Therapeutics Past Earnings Performance

Past criteria checks 0/6

Compass Therapeutics's earnings have been declining at an average annual rate of -4.7%, while the Biotechs industry saw earnings growing at 15.5% annually.

Key information

-4.7%

Earnings growth rate

54.8%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-28.9%
Net Margin	n/a
Last Earnings Update	31 Mar 2024

Recent past performance updates

No updates

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

Revenue & Expenses Breakdown

How Compass Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:CMPX Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	-45	12	41
31 Dec 23	-42	12	38
30 Sep 23	-41	12	36
30 Jun 23	-43	12	37
31 Mar 23	-40	12	32
31 Dec 22	-39	12	30
30 Sep 22	-41	12	30
30 Jun 22	-35	12	23
31 Mar 22	-82	11	20
31 Dec 21	-82	11	20
30 Sep 21	-78	11	15
30 Jun 21	-81	13	16
31 Mar 21	-31	13	16
31 Dec 20	-29	13	15
30 Sep 20	-28	12	14
30 Jun 20	-27	9	16
31 Mar 20	-30	11	19
31 Dec 19	-35	12	22

Quality Earnings: CMPX is currently unprofitable.

Growing Profit Margin: CMPX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CMPX is unprofitable, and losses have increased over the past 5 years at a rate of 4.7% per year.

Accelerating Growth: Unable to compare CMPX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).

Return on Equity

High ROE: CMPX has a negative Return on Equity (-28.93%), as it is currently unprofitable.

Compass Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Compass Therapeutics, Inc. Announces Management Changes

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Compass Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

New minor risk - Shareholder dilution

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$80k worth of stock

Co-Founder recently bought US$77k worth of stock

Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit Committee

Price target increased to US$9.46

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy

President & COO recently sold US$97k worth of stock

Price target increased to US$9.67

High number of new and inexperienced directors

Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investors

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

High number of new and inexperienced directors

Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022

High number of new and inexperienced directors

Co-Founder recently bought US$61k worth of stock

Co-Founder recently bought US$50k worth of stock

Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

High number of new and inexperienced directors

Price target decreased to US$8.86

Compass Therapeutics Announces Management Appointments

Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Compass Therapeutics, Inc. Announces Resignation of Brett Kaplan of the Board of Directors

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

High number of new and inexperienced directors

Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies